Zinzino AB (publ) (ZZ-B.ST) fair value

ACCE thesis

Zinzino sells direct-to-consumer nutritional supplements, most notably its BalanceOil omega-3 range and a line of Vitamin D and wellness products, sold through a network of independent consultants rather than retail shelves. The structural argument is the economics of that model: a 55.5% ROE and a 14.9% operating margin on a 29.9% gross margin point to a capital-light business that converts revenue into cash without heavy inventory or store costs. Revenue growth of 17.9% is solid for a Consumer Defensive name, and the 12.7x trailing P/E sits well below the 23.6x forward multiple, which means earnings are expected to fall or the forward figure reflects a different base, so the reader should check consensus before reading the gap as value. The Nordic small-cap listing and absence from any index limit the liquidity and institutional attention the stock gets, which is part of why it can trade at an apparent discount. It is worth a deeper look to confirm whether the forward earnings decline is real, how much of the growth comes from consultant recruitment versus repeat customer spend, and whether the margin structure holds as the business scales.